Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
Abstract Background Long-acting somatostatin analogs (LA SSAs) are approved and recommended for the treatment of patients with advanced neuroendocrine tumors (NETs). Given the long duration of therapy and differences in administration routes, it is important to understand patients’ experiences with...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-09-01
|
Series: | Journal of Patient-Reported Outcomes |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41687-021-00355-5 |